Datasheet: MCA1037F

BATCH NUMBER 164017

Description:	RAT ANTI DOG CD5:FITC
Specificity:	CD5
Format:	FITC
Product Type:	Monoclonal Antibody
Clone:	YKIX322.3
Isotype:	IgG2a
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat - 1/10

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only.It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Target Species

Dog

Product Form

Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid

Max Ex/Em

Fluorophore	Excitation Max (nm)	Emission Max (nm)
FITC	490	525

Preparation

Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.09% sodium azide (NaN_3)
1% bovine serum albumin

Approx. Protein Concentrations

IgG concentration 0.1 mg/ml

Immunogen	Concanavilin A activated canine peripheral blood cells
RRID	AB_322643
Fusion Partners	Spleen cells from an immunized DA rat were fused with cells of the rat Y3/Ag1.2.3 myeloma cell line
Specificity	**Rat anti Dog CD5 antibody, clone YKIX322.3** recognizes canine CD5, a 67 kDa cell surface type 1 transmembrane glycoprotein also known as lymphocyte antigen T1, Ly-1 or Leu-1. CD5 is expressed on the surface of T-cells and thymocytes, CD5 is also expressed by NK cells at low levels (Huang *et al.* 2008). Rat anti dog CD5, cloneYKIX322.3 was clustered as canine CD5 in the First Canine Leucocyte Antigen Workshop (Cobbold *et al.* 1994). In a study of 73 cases of canine chronic lymphocytic leukemia (CLL) CD5 expression was absent on all cases of B-cell CLL as defined by CD21 expression and lack of CD3 or other T cell antigen expression (Vernau and Moore 1999). Rat anti dog CD5 serves as a useful marker for the discrimination of canine leukemias of differing origins (Deravi *et al.* 2017).
Flow Cytometry	Use 10µl of the suggested working dilution to label 10^6 cells or 100µl of whole blood
References	1. Cobbold, S/ & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens. 43 (3): 137-54. 2. Hewicker-Trautwein, M. *et al.* (1999) Immunocytochemical demonstration of lymphocyte subsets and MHC class II antigen expression in synovial membranes from dogs with rheumatoid arthritis and degenerative joint disease. Vet Immunol Immunopathol. 67 (4): 341-57. 3. Vernau, W. & Moore, P.F. (1999) An immunophenotypic study of canine leukemias and preliminary assessment of clonality by polymerase chain reaction. Vet Immunol Immunopathol. 69: 145-64. 4. Guarga, J.L. *et al.* (2002) Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. Vet Immunol Immunopathol. 88: 13-20. 5. Burnett, R.C. *et al.* (2003) Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet Pathol. 40: 32-41. 6. Lamerato-Kozicki, A.R. *et al.* (2006) Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol. 34 (7): 870-8. 7. Fosmire, S.P. *et al.* (2007) Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma. Vet Pathol. 44: 467-78. 8. Huang, Y.C. (2008) CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. J Leukoc Biol. 84: 1501-10. 9. Araújo, M.S. *et al.* (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. Vet Immunol Immunopathol. 141: 64-75. 10. GomesMde, O. *et al.* (2011) Old beagle dogs have lower faecal concentrations of some fermentation products and lower peripheral lymphocyte counts than young adult beagles. Br J Nutr. 106 Suppl 1: S187-90.

11. Rütgen, B.C. *et al.* (2012) Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model. PLoS One. 7 (6): e40078.
12. Michael, H.T. *et al.* (2013) Isolation and characterization of canine natural killer cells. Vet Immunol Immunopathol. 155 (3): 211-7.
13. Aricò, A. *et al.* (2013) The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: *in vivo* and *in vitro* study. BMC Vet Res. 9: 94.
14. Aresu, L. *et al.* (2014) VEGF and MMP-9: biomarkers for canine lymphoma. Vet Comp Oncol. 12: 29-36.
15. Gelain, M.E. *et al.* (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood. Vet Immunol Immunopathol. 159 (1-2): 91-6.
16. Stokol, T. *et al.* (2015) Alkaline phosphatase is a useful cytochemical marker for the diagnosis of acute myelomonocytic and monocytic leukemia in the dog. Vet Clin Pathol. 44 (1): 79-93.
17. Ito, D. *et al.* (2015) A double blinded, placebo-controlled pilot study to examine reduction of CD34 $^{+}$/CD117 $^{+}$/CD133 $^{+}$ lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma. F1000Res. 4: 42.
18. Bonnefont-Rebeix, C. *et al.* (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology. Immunobiology. 221 (1): 12-22.
19. Gibbons, N. *et al.* (2017) Phenotypic heterogeneity of peripheral monocytes in healthy dogs. Vet Immunol Immunopathol. 190: 26-30.
20. Deravi, N. *et al.* (2017) Specific immunotypes of canine T cell lymphoma are associated with different outcomes. Vet Immunol Immunopathol. 191: 5-13.
21. MariaA, P.J. *et al.* (2017) The effect of age and carbohydrate and protein sources on digestibility, fecal microbiota, fermentation products, fecal IgA, and immunological blood parameters in dogs. J Anim Sci. 95 (6): 2452-66.
22. Roatt, B.M. *et al.* (2017) A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden. Front Immunol. 8: 217.
23. Karayannopoulou, M. *et al.* (2017) Evaluation of blood T-lymphocyte subpopulations involved in host cellular immunity in dogs with mammary cancer. Vet Immunol Immunopathol. 186: 45-50.
24. Lin, C.S. *et al.* (2018) Activating natural killer (NK) cytotoxicity of canine CD5^{-}CD21^{-} cells requires low surface CD5 density NK cells. Iran J Vet Res. 19 (2): 87-95.
25. Graves, S.S. *et al.* (2019) Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody. Vet Immunol Immunopathol. 211: 10-8.
26. Martini, V. *et al.* (2019) Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy. Res Vet Sci. 125: 130-5.
27. Wolf-Ringwall, A. *et al.* (2020) Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol. Vet Comp Oncol. 18 (3): 342-52.
28. Aguiar-Soares, R.D.O. *et al.* (2020) Phase I and II Clinical Trial Comparing the LBSap, Leishmune®, and Leish-Tec® Vaccines against Canine Visceral Leishmaniasis. Vaccines (Basel). 8 (4)Nov 17 [Epub ahead of print].

29. Sayag, D. *et al.* (2020) Proof-of-concept study: Evaluation of plasma and urinary electrolytes as markers of response to L-asparaginase therapy in dogs with high-grade lymphoma. Vet Clin Pathol. 49 (3): 476-83.
30. Lee, J. *et al.* (2021) Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor. Biomed Res Int. 2021: 6690704.
31. Grudzien, M. *et al.* (2021) A newly established canine NK-type cell line and its cytotoxic properties. Vet Comp Oncol. 19 (3): 567-77.
32. Lee, S.H. *et al.* (2021) Safety and immunological effects of recombinant canine IL-15 in dogs. Cytokine. 148: 155599.
33. Karayannopoulou, M. *et al.* (2022) Effect of major versus minor mastectomy on host immunity in canine mammary cancer Vet Immunol Immunopathol. 24 Feb: 110403.
34. Riccardo, F. *et al.* (2022) Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. J Immunother Cancer. 10 (5): e004007. [Epub ahead of print].
35. Jaensch, S. *et al.* (2022) Clinicopathologic and immunophenotypic features in dogs with presumptive large granular lymphocyte leukaemia Australian Veterinary Journal. [Epub ahead of print].
36. Martini, V. *et al.* (2018) A retrospective study of flow cytometric characterization of suspected extranodal lymphomas in dogs. J Vet Diagn Invest. 30 (6): 830-836.
37. Lee, G.W. *et al.* (2021) Case Report: Long-Term Survival of a Dog With Chronic Lymphocytic Leukemia Treated With Chlorambucil, Prednisolone, and Imatinib. Front Vet Sci. 8: 625527.
38. Hughes, K. *et al.* (2024) Canine T zone lymphoma is a tumor of mature, previously activated αβ T cells Vet Immunology Immunopathol 110725.
39. Sheng, R. *et al.* (2023) Prognostic significance of CD25 expression in dogs with a noninvasive diagnosis of B-cell lymphoma treated with CHOP chemotherapy. Vet Comp Oncol. 21 (1): 28-35.

Storage	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C. Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Guarantee	12 months from date of despatch
Health And Safety Information	Material Safety Datasheet documentation #10041 available at: https://www.bio-rad-antibodies.com/SDS/MCA1037F 10041
Regulatory	For research purposes only

Related Products

Recommended Negative Controls

RAT IgG2a NEGATIVE CONTROL:FITC (MCA6005F)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	**Worldwide**	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	**Europe**	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M407896:221010'

Printed on 05 Mar 2024